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Background: The conformational preferences of a number of peptides with
sequences related to the envelope glycoproteins of HIV-1 have been
investigated in the past few years. Similar studies have not been made for HIV-2,
which is a distinct virus with similar physiological effects to those of HIV-1. The
discovery of common structural features would be a promising route to the
design of immunogens for generally effective HIV vaccines. We present the
results of an NMR conformational study of a sequence deriving from the V3 loop
of HIV-2.
Results: Three synthetic immunogenic peptides were studied, of 12, 22 and 39
amino acids in length, all containing a central Met-Ser-Gly-Arg sequence
conserved among a number of HIV-2 isolates. In addition, the 39-mer contained
a disulfide bond between cysteine residues close to the ends of the molecule,
forming a loop that is thought to comprise an important structural and
immunological component of the intact glycoprotein. All three peptides display
well defined b-turns in the Met-Ser-Gly-Arg sequence, independent of the
integrity of the disulfide bond. No other conformational preferences for folded
conformations were found for the peptides. 
Conclusions: The presence of a b-turn in the Met-Ser-Gly-Arg sequence is
strikingly similar to the behavior seen for the corresponding principal neutralizing
determinant sequence from gp120 of HIV-1 and argues, in the absence of
information on the three-dimensional structure of the intact proteins, for a
similarity in the structure of this region that could be exploited in the design of
synthetic peptide vaccines generally effective against HIV infections.
Introduction
There are two distinct types of human lentiviruses: human
immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-
2). The envelope glycoproteins of HIV-1 and HIV-2,
gp120 and gp125 respectively, play a major role in the
infection of T cells, which occurs through binding of the
envelope glycoproteins on the surface of the viruses and
virus-infected cells to CD4 present on the T-cell surface.
Abrogation of binding of the envelope glycoproteins to
CD4 would presumably hinder or prevent infection, and a
number of studies have focused on means to achieve this,
including treatment with soluble CD4 and the production
of antibodies. The envelope glycoproteins are in general
the targets for neutralizing antibodies and the most
immunologically visible portions of their sequences have
potential for use as subunit vaccines in HIV-1 and HIV-2
infections in humans. 
The major determinants involved in induction of immune
protection in HIV infections have been extensively exam-
ined in HIV-1. In these studies one dominant strain-spe-
cific linear antigenic site, referred to as the principal neu-
tralizing determinant (PND), was demonstrated [1,2] and
located within a disulfide-linked loop in the V3 region of
envelope glycoprotein gp120 [1,3,4]. The homologous V3
region of gp125 in HIV-2 also plays an important role in
induction of neutralizing antibodies [5]. This was demon-
strated by induction of a neutralizing antibody response in
animals hyperimmunized with selected peptides [5] and
also by blocking of the neutralizing capacity of sera from
HIV-2-infected individuals with peptides representing the
V3 loop [6].
LaRosa et al. [7] analyzed the amino acid sequences of the
PND of 245 different isolates of HIV-1 and found that the
sequence Gly-Pro-Gly-Arg was conserved in 84% of the
PND sequences, and that the first three amino acids in
this sequence, Gly-Pro-Gly, were conserved in 97% of
them. The Gly-Pro-Gly sequence and the two flanking
regions in HIV-1 are called the GPG crest. The variability
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of the amino acids in the flanking regions of the GPG
crest from different PND sequences gives rise to different
antigenic specificities from different HIV-1 isolates.
Unfortunately, antisera raised against the PND of one
isolate generally do not neutralize other isolates [1,2,8,9].
However, antisera directed against the slightly longer
sequence Gly-Pro-Gly-Arg-Ala-Phe were shown to neu-
tralize multiple isolates of HIV-1 [4]. Thus, the conserved
GPG crest sequence may be the most appropriate candi-
date for a vaccine capable of producing antibodies able to
neutralize the majority of HIV-1 strains. 
The V3 amino acid sequences of HIV-2 isolates show a
greater stability, with only 7% variation compared to 16%
found in different HIV-1 strains [10]. Further, a broad
cross-neutralizing activity including many primary HIV-2
isolates from Guinea–Bissau has been demonstrated with
animal hyperimmune sera against V3 loop peptides [6].
Fine mapping of important individual amino acids for
binding of monoclonal antibodies directed against the V3
loop of HIV-2 revealed two immunogenic sites: Phe-His-
Ser and Trp-Cys-Arg [6]. Similar results were obtained in
another study employing a different V3 monoclonal anti-
body [11], but the specificity of this antibody was for
amino acids 316–318, His-Tyr-Gln, rather than the
315–317 sequence, Phe-His-Ser, mentioned above.
Several groups have studied the solution conformations of
immunogenic peptides deriving from the PND of differ-
ent HIV-1 isolates [12–16]. A significant population of
conformations containing a b-turn was found in all cases in
the conserved crest sequence Gly-Pro-Gly-Arg [12–14,16]
or in the sequence Gly-Pro-Gly-Gln from the V3 loop of a
Thailand HIV-1 isolate [15]. The structural features of the
HIV-1 PND have also been investigated by determining
the conformation of PND peptides bound to neutralizing
monoclonal anti-peptide antibodies [17,18]. The two anti-
bodies 50.1 and 59.1 bind to overlapping epitopes within
the V3 loop, and both structures show evidence of a b-turn
in the GPG crest sequence Gly-Pro-Gly-Arg as observed
in solution. 
Although several studies have focused on the V3 loop
from gp120 of HIV-1, little effort has been directed
towards determining the structure of the corresponding
region of HIV-2. In this paper, we present a two-dimen-
sional 1H-NMR solution study of immunogenic peptides
from the PND region of gp125 from the HIV-2 strain
HIV-2ISY. A conserved sequence found in the HIV-2 V3
region corresponds to the HIV-1 PND, the GPG crest.
This is the sequence Met-Ser-Gly-Arg (the Arg of the ISY
strain is replaced by a Leu in most strains), in which the
Gly-Pro in the GPG crest is replaced by a Met-Ser. A con-
servation of the amino acids in the HIV-2 V3 region
extends for about five further residues towards the C ter-
minus of the Met-Ser-Gly-Arg sequence to include the
two overlapping sites identified with the two different
monoclonal antibodies [6,11]. 
In order to examine the conformational preferences of the
conserved Met-Ser-Gly-Arg and the following sequence in
HIV-2 V3, as well as the role of the disulfide bond, we
have synthesized and examined the solution conforma-
tional preferences of three synthetic peptides of different
lengths, all corresponding to the sequence of the V3 loop
region of HIV-2, and all containing the conserved Met-
Ser-Gly-Arg sequence. Only the longest peptide, of 39
amino acids, contains the cognate disulfide bond between
two cysteine residues (at positions 3 and 37 of the peptide)
that is present in the intact gp125 protein. The absence of
the disulfide in the 22-mer and 12-mer peptides permits
an evaluation of the requirement for the disulfide bridge
in the stabilization of secondary and tertiary conformation
around the conserved Met-Ser-Gly-Arg sequence. 
Structural information on the HIV-2 PND deriving from
this study can be combined with structural and immuno-
logical data already obtained on the HIV-1 PND in order
to gain insight on the role of conformation in eliciting
immunological response. Ultimately, this should aid in the
design of synthetic peptide vaccines effective against
HIV-1 and HIV-2 infections in humans.
Results and discussion
Design of the peptides
The observation of folded forms of peptides is in some
cases related to the length of the peptide [19,20].
However, turn conformations appear to persist in even
quite short peptides [21]. In order to assess firstly whether
a turn conformation formed in the sequence Met-Ser-Gly-
Arg, as it does in the corresponding HIV-1 sequence, and
secondly whether conformational preferences for other
elements of secondary structure could be detected in
longer peptides including this sequence, we have studied
three peptides of varying length, all including the Met-
Ser-Gly-Arg sequence. The peptides are aligned accord-
ing to their sequence identity in Figure 1. Numbering of
residues in text, tables and figures is made according to
the sequence of the 39-mer. 
Resonance assignments and chemical shifts
The 1H-NMR resonance assignments of the 39-mer, 22-
mer and 12-mer at 5°C were determined by conventional
methods [22,23] and are available in Table 1 of the Sup-
plementary material (published with this paper on the
internet). The strong similarity in backbone proton chem-
ical shifts of residues common to the three peptides is
illustrated in Figure 2, which shows the fingerprint region
of the 2QF COSY spectra of the 39-mer, 22-mer and 12-
mer. Several cross peaks, corresponding to the NH-CaH
COSY connectivities of common residues, are clearly
present in the same position in each spectrum. These
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include the residues corresponding to the conserved Met-
Ser-Gly-Arg sequence. The conserved backbone proton
chemical shifts of these four residues suggest that all
three peptides display a very similar conformation for this
stretch of sequence. 
Conformational flexibility of the peptides
The presence of an ordered conformation in a peptide in
solution is indicated, by analogy with the observations for
proteins [22], by characteristic NOE connectivities in the
NOESY spectrum [23]. A stretch of sequential dNN(i,i+1)
connectivities accompanied by medium-range dab(i,i+3)
and daN(i,i+3) connectivities provides NMR evidence for
a helical conformation. Conversely, evidence for an
extended, perhaps b but most likely disordered, confor-
mation is provided by a stretch of sequential daN(i,i+1)
connectivities. The daN fingerprint and dNN regions of the
NOESY spectrum of the 39-mer are shown in Figure 3.
The NOESY spectra of the 22-mer and 12-mer are very
similar for corresponding residues (data not shown). The
NOE connectivities observed in the NOESY spectra of
the 39-mer, 22-mer and 12-mer are summarized in
Figure 4. Although dNN(i,i+1) connectivities are observed
in the spectra of each peptide, no evidence is found of
dab(i,i+3) or daN(i,i+3) connectivities, suggesting that
there is no strong tendency for any of the peptides to
adopt a helical conformation in solution. Long uninter-
rupted stretches of daN(i,i+1) connectivities are found in
each peptide, however, suggesting that the conforma-
tional ensemble of these peptides in solution is largely
disordered. The presence of both dNN(i,i+1) and
daN(i,i+1) connectivities for the same residues is a strong
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Figure 1
Amino acid sequences of the three peptides
from HIV-2 gp125 V3, aligned to indicate their
sequence identity. The boxed Met-Ser-Gly-Arg
region indicates the conserved sequence in
the PNDs of various HIV-2 isolates. The
numbers directly above the residues
correspond to the sequence number in that
peptide, referred for all three peptides to the
sequence of the 39-mer. The second set of
numbers extending from 294 to 332
corresponds to the sequence number in the
intact gp125 protein. 
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Figure 2
Fingerprint regions of the 600 MHz 1H-NMR 2QF COSY spectra of
the (a) 39-mer, (b) 22-mer and (c) 12-mer. All peptides are 5 mM in
90% 1H2O/10% 2H2O, pH 4.5–4.6, at 5°C. Asterisks refer to cross
peaks that have not been assigned and that may arise from cis/trans
isomerism at Pro6 (see text).
indication that the peptides are highly flexible and sample
many conformations, including those in both the b
(extended) and a (helical) regions of the Ramachandran
map. For the great majority of the residues in each
peptide, no conformational preference is seen for any
folded forms. 
A qualitative assessment of the secondary structure and
flexibility of the three peptides is provided by a compari-
son of the backbone proton chemical shifts with those
observed in random peptides. Such a comparison is made
in Figure 5, where the differences between backbone
proton chemical shifts and their random coil values are cal-
culated. Consistent deviations of CaH and NH chemical
shifts from random-coil values are indicative of secondary
structure [24]. All 20 naturally occurring amino acids expe-
rience a mean CaH shift of –0.39 ppm (upfield from the
random coil value) when placed in a helical configuration,
whereas an average downfield shift of 0.37 ppm is
observed when the residue is placed in a b-strand or
extended configuration [24]. Figure 5a indicates that none
of the CaH chemical shifts differs from the corresponding
random coil value [25] by more than ± 0.3 ppm, a strong
indication that the peptides are disordered and have no
conformational preferences for folded forms. The largest
deviations in CaH chemical shift are observed for two of
the residues immediately preceding proline residues,
Val12 and Lys31. No such deviation is observed for Arg5,
immediately preceding Pro6, possibly because of the
influence of the nearby disulfide bond.
The comparison of the NH chemical shift with the
random coil value in general gives information on hydro-
gen bonding. A hydrogen bond causes deshielding of the
proton, with a resultant downfield shift. For most peptides
in water solution, however, all of the amide protons are
completely hydrated, with strong hydrogen-bonding inter-
actions. Partial desolvation and intramolecular hydrogen
bond formation therefore results in a lowering of the
strength of the hydrogen bond to a given amide proton,
giving a diagnostic upfield shift. This is seen in Figure 5b,
particularly in the case of the amide proton of Arg20,
which is involved in a hydrogen-bonded turn structure
(see below).
The conformational flexibility suggested by the NOEs
and chemical shifts is supported by the 3JHN,Ha coupling
constants measured for each peptide (shown in Fig. 4).
The majority of 3JHN,Ha coupling constant values are
between 6 and 8 Hz, indicating that the peptides are flexi-
ble. Further evidence for peptide flexibility comes from
calculation of the ratio of the daN(i,i) and daN(i,i–1) NOEs,
dNa/daN. The NH(i)–CaH(i) distance is covalently fixed
in the 2.7–3.1 Å range for a-helix and b-strand, whereas
the NH(i)–CaH(i–1) distance is 3.4–3.6 Å for a-helix and
2.2–3.1 for b-strand. Consequently, the dNa/daN ratio is
> 1.1 for a-helix and < 0.83 for b-strand [26]. The magni-
tude of this ratio is dependent mainly on the c dihedral
angle of residue (i–1), so for dNa/daN > 1.1, c(i–1) is in
the a-helical region of conformational space, whereas for
dNa/daN < 0.83, y(i–1) is in the b region of conforma-
tional space. Measurement of dNa/daN ratios for all possi-
ble residues in the three peptides yields values 0.83 <
dNa/daN < 1.1, suggestive of no strong preferences for a-
helix or b-strand in any of the three peptides. 
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Figure 3
600 MHz 1H NOESY spectrum of the 39-mer showing (a) the
CaH–NH region and (b) the NH–NH region. The 39-mer was 5 mM in
90% 1H2O/10% 2H2O, pH 4.5 at 5°C.
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Cis and trans isomers
The 39-mer sequence contains three prolines, Pro6, Pro13
and Pro32, whereas the 22-mer peptide sequence contains
only one proline, Pro13. Any of these prolines could
provide a site for isomerization leading to cis and trans
isomers around the X–Pro peptide bond, although none of
them contains the aromatic-Pro sequence that is most
favorable for the cis form [27,28]. Diagnostic dad(i,i+1)
NOEs are visible for each of the prolines, confirming that
the major configuration at each proline is trans. Eight
isomers could potentially exist in solution for the 39-mer
and two for the 22-mer. There is no strong evidence for
the presence of additional species with isomerized pro-
lines in either peptide, although Figure 2a contains a small
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Figure 4
Schematic diagram showing the magnitude of
NOE connectivities observed in NOESY
spectra of the (a) 39-mer, (b) 22-mer and (c)
12-mer, and including coupling constants
(3JHN,Ha in Hz) and temperature coefficients
(–Dd/DT, in ppb K–1). Cross-hatched boxes
indicate connectivities observed to the CdH of
a proline residue in place of the NH, and
asterisks indicate connectivities that are
present but overlapped.
Figure 5
Plots of the difference in NMR chemical shift
(observed–random coil) for (a) the CaH
proton Dd(CaH)obs–coil and (b) the backbone
NH proton Dd(NH)obs–coil versus residue
position for the 39-mer (black box), 22-mer
(white box), and 12-mer (cross-hatched box).
The residue position is given by the peptide
sequence of the 39-mer, and the 22-mer and
12-mer sequences are aligned accordingly.
Data are measured from 1H-NMR spectra
taken at pH 4.5–4.6, 5°C.
number of low intensity resonances beside some of the
NH-CaH cross peaks, particularly those for the first five
residues. These additional cross peaks could arise from
cis/trans isomerism around Pro6, but there is no sign of the
daa(i,i+1) NOE connectivity diagnostic for a cis peptide
between any of these resonances. 
Presence of a b-turn conformation in the 39-mer, 22-mer
and 12-mer
Although none of the peptides appears to contain defined
regions of a-helix or b-strand, strong evidence is found of
a b-turn conformation in the conserved Met-Ser-Gly-Arg
sequence in each peptide from NOESY spectra, tempera-
ture coefficients and coupling constant information. 
The NOEs diagnostic of b-turns include a dNN(i,i+1)
NOE between residues 3 and 4 of the turn, corresponding
to a distance of 2.4 Å, and a daN(i,i+2) NOE between
residues 2 and 4, corresponding to a distance of 3.6 Å in
the type I turn and 3.3 Å in the type II turn, and a strong
dNN(3,4) cross peak in both types of turns. Type I and
type II turns may be distinguished by the relative
strengths of the daN(2,3) cross peak (stronger for type II)
and the dNN(2,3) cross peak (stronger for type I). Positive
determination of the presence of type I turns in the con-
formational ensemble is provided by the observation of a
dNN(i,i+1) NOE between residues 2 and 3 of the turn. The
observation of a daN(i,i+1) NOE between these two
residues cannot be used to infer type II turns directly,
however, because of the presence in the conformational
ensemble of the peptide of unfolded forms, which also
give rise to strong daN(i,i+1) NOEs.
The 39-mer, 22-mer and 12-mer show the diagnostic
NOEs characteristic of a b-turn in the region Met17-
Ser18-Gly19-Arg20. The strongest dNN(i,i+1) NOE for
each peptide is between Gly19 and Arg20, as expected for
a turn, and a daN(i,i+2) NOE is clearly visible between
Ser18 and Arg20 (this is illustrated in Fig. 3, where the
connectivities characteristic of the turn are labeled). The
presence of dNN(2,3) cross peaks between Ser18 and
Gly19 for each of the three peptides suggests the presence
of type I conformers in the ensemble, but the relative
sizes of the daN(2,3) and dNN(2,3) NOEs (Fig. 3) indicate
that type II conformations are also present, similar to the
behavior observed for the analogous HIV-1 peptides [12].
The predominance of type II turn configuration is further
supported by the absence of any detectable dbN(2,4) con-
nectivities between Ser18 and Arg20. The distance
between the CbH of residue 2 of the turn and the NH of
residue 4 can be as small as 2.9 Å in a type I turn, but
remains longer than 3.6 Å in a type II turn.
Additional evidence for the b-turn in the region Met17-
Ser18-Gly19-Arg20 is afforded by the small temperature
coefficient of the Arg20 backbone amide in each of the
three peptides (see Fig. 4). The temperature dependence
of the amide proton chemical shift is an indication of pos-
sible intramolecular hydrogen bonding. For a random coil
peptide in water, the temperature coefficients of the
amide proton resonances are expected to be
6#–Dd/DT#10 ppb K–1, whereas for amides protected
from exchange with the solvent these values are expected
to decrease to –Dd/DT#5 ppb K–1 [29]. The temperature
coefficients of Arg20 in the three peptides indicate that its
amide proton is protected from exchange with solvent, a
likely consequence of its involvement in the (1,4) hydro-
gen bond present between the carbonyl oxygen of the first
residue in the putative turn and the amide hydrogen of
the last residue in the turn (Met17 CO–Arg20 NH).
In addition, the 3JHN,Ha coupling constants for Ser18, the
residue in position 2 of the turn, are less than or equal to
6 Hz in the three peptides (see Fig. 4), consistent with a f
angle > –70, compared with f2 = –60 for most turns [30].
Rough calculations can be made to quantitate turn popula-
tions in the three peptides. With the understanding that
accurate measurements of folded form from a population
of flexible peptides in solution is difficult to obtain, we
have used a method developed by Yao et al. [28], adapted
to estimate the turn population from the 3JHN,Ha coupling
constants measured for the residue in position 2 of the
turn, i.e. Ser18. A two-site model was used in which Ser18
could find itself in either a turn conformation or in an
extended conformation. Assuming 100% turn conforma-
tion, the coupling constants for Ser18 should be 3JHN,Ha =
4 Hz corresponding to a f = –60 [31]. Assuming 100%
extended conformation, coupling constants of 3JHN,Ha =
9 Hz are expected corresponding to a f < –100 [31]. Using
these two extreme values of 3JHN,Ha and the measured
3JHN,Ha values, an estimate of the percentage of turn or
extended conformation was made for Ser18. Values were
obtained of 65% for the 39-mer peptide, 80% for the 22-
mer peptide, and 65% for the 12-mer peptide. Thus, from
these rough estimates it would appear that about 70% of
the population of the three peptides in solution is folded
into a turn conformation around the region Met17-Ser18-
Gly19-Arg20.
Influence of the disulfide bond on conformational
preferences
The 39-mer peptide was studied in its oxidized state with
the two cysteines (Cys3 and Cys37) disulfide-bridged as
they are in the intact gp125 protein. However, the 22-mer
and the 12-mer do not contain the disulfide bridges, as the
cysteines are not included in their shorter sequences. This
permits an evaluation of the requirement of the disulfide
bridge in the stabilization of secondary and tertiary
peptide conformation. All three peptides display a well
populated turn conformation in solution spanning the
region Met17-Ser18-Gly19-Arg20. Thus, the presence of
an intact disulfide bridge does not seem to be prerequisite
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for the formation of the turn. The formation of the turn is
also independent of the length of the peptide, at least
above a lower threshold of 12 residues. 
The presence of b-turns and correlation to antigenicity
From the wealth of X-ray crystal structures of
antibody–peptide complexes that have recently emerged
in the literature, it is clear that the most common antibody
recognition motif in a peptide is a b-turn [18,32–36]. NMR
studies of peptide antigens [12,13,16,21,37–42] along with
secondary structure predictions show that antigenic pep-
tides have a strong tendency to adopt stable b-turn confor-
mations in the absence of antibody. In fact, features
incorporated into peptide antigens which stabilize b-turns
have been shown to increase antibody affinity [39,43]. 
In this NMR study, we show evidence for a well defined
b-turn in the Met-Ser-Gly-Arg sequence within the PND
region of HIV-2 gp125. Fine mapping of the antigen-
binding sites of two monoclonal antibodies directed
against V3 loop peptides has indicated that an area adja-
cent to the turn is most important in binding [6,11].
Although we observe no marked solution conformational
preference for this part of the sequence, its close proxim-
ity to the turn may well be a means of potentiating
binding. This discovery coupled with a previous finding of
a stable b-turn in the homologous stretch of residues (Gly-
Pro-Gly-Arg) within the PND region of HIV-1 gp120 [12]
suggests that these turn regions may be the best targets for
the design of a synthetic peptide vaccine effective against
HIV-1 and HIV-2 infections. One of the goals in the
development of synthetic vaccines is to engineer a
peptide immunogen that optimizes the desired immuno-
logical response. The engineering of HIV-1 and HIV-2
synthetic peptide vaccines with increased stability of the
b-turn structural elements may lead to a vaccine with
enhanced immunogenicity. 
Materials and methods
Peptide synthesis
The HIV-2 gp125 V3 peptides used in this study were synthesized by
solid phase peptide synthesis and purified by reversed-phase HPLC as
previously reported [44,45]. The 22-mer and 12-mer peptides were C-
terminal amides, N-terminal acetylated, whereas the 39-mer peptide
was C-terminal amidated, with a free N-terminal amine group. Amino
acid analysis was performed on a Beckman model 6300 amino acid
analyzer (Beckman, San Ramon, CA). Mass analysis of the peptides
was performed on a Fisons VG Quattro triple quadruple mass spec-
trometer (Manchester, England) fitted with an electrospray ionization
source operating in positive ion mode. 10 ml injections of the peptide
samples (usually in aqueous acetonitrile containing 0.05% of trifluo-
roacetic acid at an approximate concentration of 50 pmol ml–1) were
made into a carrier solution composed of 1:1 (v/v) water : acetonitrile
containing 0.05% of trifluoroacetic acid at a rate of 10 ml min–1 into the
electrospray source. The quadrupoles were scanned from 600–1400
mass over charge ratio at 10 s scan–1. Data were acquired in the MCA
mode with typically 10–15 scans being summed to produce a spec-
trum. The 39-mer was studied in its oxidized form with the disulfide
bridge between residues Cys3 and Cys37 (Fig. 1). The intramolecular
disulfide bridge was obtained by air oxidation. The reduced 39-mer
was dissolved in 100 mM NH4HCO3, pH 8.0 at a total concentration of
approximately 0.2 mg ml–1 and the solution magnetically stirred for
24 h while exposed to air. Verification of the intradisulfide bridge was
determined by both reversed-phase HPLC retention change and elec-
trospray mass spectroscopy as described above.
NMR sample preparation
Samples were prepared in 90% 1H2O/10% 2H2O to a concentration of
5 mM. 2,2-dimethyl-2-sila-5-pentanesulfonate (DSS) was added as an
internal chemical shift reference and the pH subsequently adjusted to
between 4.5 and 4.6 using small aliquots of NaOH and HCl solutions.
No signs of concentration-dependent changes in the NMR spectra
were observed, and the linewidths of the resonances are appropriate
for monomeric forms of each peptide. 
NMR spectroscopy
1H-NMR spectra for the 39-mer were acquired at 600 MHz using a
Varian Unity 600 spectrometer. 1H-NMR spectra for the 22-mer and
12-mer were acquired at 500 MHz using a Bruker AM500 NMR spec-
trometer equipped with digital phase shifting hardware. 2QF COSY
[46,47], TOCSY [48,49], and NOESY [50,51] data sets were
acquired for each peptide. Mixing times of 300 ms (39-mer) and
400 ms (22-mer and 12-mer) were used in the NOESY spectra and
80 ms in the TOCSY spectrum. Suppression of the water peak was
achieved by presaturation for 2.0 s at a power level of 28 dB (gB2 =
50 Hz). All experiments were carried out at 5°C to minimize amide
exchange. Typical data sets for the 39-mer were acquired using the
hypercomplex method [52] with spectral widths of 7000 Hz in each
dimension and incorporating 32 transients for each of 300 increments
with 4096 data points along t2. Typical data sets for the 22-mer and
12-mer were acquired using the TPPI method [53] with spectral widths
of 6000 Hz in each dimension and incorporating 32 transients for each
of 500–600 increments with 4096 data points along t2.
Spectra for the 39-mer were processed on a Sun workstation using
Varian software. Spectra for the 22-mer and the 12-mer were
processed on a Silicon Graphics work station using Felix 2.3 software
interfaced with an Insight II environment (1993 Biosym Technologies,
Inc). All two-dimensional spectra were Fourier transformed using a
phase-shifted sine bell window function and zero-filled to 4K × 4K.
Measurement of temperature coefficients
Temperature coefficients (–Dd/DT; ppb K–1) were calculated for the
amide protons of each peptide from the gradient of the linear plot of
amide proton chemical shift versus temperature. Amide proton chemi-
cal shifts for the 39-mer were obtained from NOESY spectra acquired
at 5.0, 10.0, 15.0, and 20.0, and 25.0°C. Amide proton chemical shifts
for the 12-mer were obtained from a series of one-dimensional spectra
acquired at 5.0, 15.0, 25.0 and 35.0°C. Similar one-dimensional
spectra obtained for the 22-mer were difficult to resolve at every tem-
perature; estimates of the temperature coefficient were made with ref-
erence to two-dimensional spectra at 5.0 and 11.0°C.
Measurement of coupling constants
3JHN,Ha coupling constants were obtained for the 39-mer from 4K × 2K
(f2 × f1) 2QF COSY spectra acquired at 5°C. The spectra were zero
filled to 16K in the f2 dimension and processed using moderate
sinebell weighting in the f1 dimension and no weighting in the f2 dimen-
sion. Traces for resolved cross peaks were taken in v2 and then curve-
fitted using a program written by R Boyko and F Sönnichsen (University
of Alberta; available from robert.boyko@ualberta.ca). 3JHN,Ha coupling
constants were obtained for the 22-mer and 12-mer from 4K x 2K (f2 ×
f1) 2QF COSY spectra acquired at 5°C. The spectra were zero filled to
4K in the f1 dimension and processed using the same weighting as for
the 39-mer. Traces for resolved cross peaks were taken in v2 and then
curve-fitted using the line-fitting algorithm for measuring coupling con-
stants available from Felix 2.3. 
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